Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

OTHER 1

Study Type

Interventional 15Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1

Interventions

venetoclax 3fludarabine phosphate 3fludarabine 3navitoclax 2ibrutinib 2brexucabtagene autoleucel 2axicabtagene ciloleucel 2asparaginase erwinia chrysanthemi recombinant 2Cyclophosphamide 2zanubrutinib 1tisagenlecleucel 1tipifarnib 1tafasitamab 1sugemalimab 1selinexor 1plerixafor 1pirtobrutinib 1nilotinib 1midostaurin 1loncastuximab tesirine 1idelalisib 1glucarpidase 1eryaspase 1ceritinib 1Whole-Body Irradiation 1Tacrolimus 1Rituximab 1Proton Pump Inhibitors 1Mycophenolic Acid 1Hydrocortisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × AP 1903 reagent × Lymphoid × Clear all
NCT03594162 2021-12-03

Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

UNC Lineberger Comprehensive Cancer Center

No longer available
LymphoidOther hematologic neoplasm

Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡